Ethacrynic acid and the treatment of glaucoma

S. Melamed*, H. Levkovitch-Verbin

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Ethacrynic acid (ECA) is a new promising drug for glaucoma. This sulfhydryl compound exerts its hypotensive effect by directly affecting the cytoskeletal properties of both trabecular meshwork cells and the inner wall of Schlemm's canal. In fact, its action resembles a 'pharmacologic trabeculocanalotomy' with subsequent increase in outflow facility. This unique mode of action may put ECA at the front of glaucoma therapy in the future.

Original languageEnglish
Pages (from-to)335-340+xi
JournalOphthalmology Clinics of North America
Issue number2
StatePublished - 1995
Externally publishedYes


Dive into the research topics of 'Ethacrynic acid and the treatment of glaucoma'. Together they form a unique fingerprint.

Cite this